The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: Interim results

Amenta, Francesco; Carotenuto, Anna; Fasanaro, Angiola Maria; Rea, Raffaele; Traini, Enea

doi:10.1016/j.jns.2012.07.003

Cited by 35 publications

(41 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Donepezil plus GPC compared to donepezil alone improved the different items analyzed except the ' Basic Activities of Daily Living ' . Interim data of ASCOMALVA suggest that the association of GPC with the standard treatment of a ChE-I may represent an option to prolong the beneficial effects of cholinergic therapies in AD with concomitant ischemic cerebrovascular injury [ 79 ].…”

Section: Treatment With Cdp-choline and Gpc: Pre-clinical And Clinicamentioning

confidence: 99%

Choline-containing phospholipids: relevance to brain functional pathways

Tayebati

Amenta

2013

Clinical Chemistry and Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Choline participates in several relevant neurochemical processes. It is the precursor and metabolite of acetylcholine (ACh), plays a role in single-carbon metabolism and is an essential component of different membrane phospholipids (PLs). PLs are structural components of cell membranes involved in intraneuronal signal transduction. This paper reviews the roles of choline and of choline-containing phospholipids (CCPLs) on brain metabolism in health and disease followed by an analysis of the effects of exogenously administered CCPLs on the brain, a topic extensively investigated by literature. Based on the observation of decreased cholinergic neurotransmission in brain disorders characterized by cognitive impairment, cholinergic precursor loading therapy with CCPLs was the first approach used to attempt for relieving the cognitive symptoms of Alzheimer ' s disease. This therapeutic strategy was discontinued due to the negative clinical results obtained with choline or lecithin. Negative results obtained with some compounds cannot be generalized for all CCPLs, as CDP-choline (citicoline) and to a greater extent choline alphoscerate (GPC) displayed interesting effects documented in preclinical studies and limited clinical trials. We provide evidence in favor of CDP-choline and GPC activity in cerebrovascular or neurodegenerative disorders characterized by cholinergic neurotransmission impairment. Based on the results of the controlled clinical trials available, we suggest that due to the lack of novel therapeutic strategies, safe compounds developed a long time ago such as effective CCPLs could have still a place in pharmacotherapy. Therefore selected compounds of this class should be further investigated by new appropriate clinical studies.

show abstract

Section: Treatment With Cdp-choline and Gpc: Pre-clinical And Clinicamentioning

confidence: 99%

Choline-containing phospholipids: relevance to brain functional pathways

Tayebati

Amenta

2013

Clinical Chemistry and Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Оригинальный препарат этой группы (Глиатилин) длительно изучался в международных ран-домизированных плацебо-контролируемых исследова-ниях и обладает достаточной доказательной базой, позволяющей свидетельствовать о доказанной эффек-тивности его использования в комбинированной тера-пии БА [2][3][4][5][6].…”

Section: для дополнительного усиления действия ингибиторов ацетилхолиunclassified

“…Полученный холин проникает через гематоэнцефалический барьер и попа-дает в головной мозг, где служит основой для образова-ния ацетилхолина. Глицерофосфат, являясь предшествен-ником фосфолипидов мембраны нейронов, стимулирует образование фосфатидилхолина, который восстанавли-вает фосфолипидный состав мембран нейронов и улуч-шает их пластичность [4][5][6].…”

Section: для дополнительного усиления действия ингибиторов ацетилхолиunclassified

“…Так, результаты двойного слепого рандомизи-рованного многоцентрового исследования ASCOMALVA (Effect of association between a ChE-I and choline alphoscerate on cognitive deficits in Alzheimer's disease associated with cerebrovascular injury -«Влияние комби-нации ингибиторов ацетилхолинэстеразы и холина аль-фосцерата на когнитивные расстройства при БА, сочета-ющейся с цереброваскулярным заболеванием») показа-ли высокую эффективность комбинации холина альфос-церата и донепезила [5]. Пациенты получали донепезил и плацебо (группа плацебо) или донепезил и холина альфосцерат (основная группа); эффективность терапии оценивалась через 3, 6, 9 и 12 месяцев лечения.…”

Section: для дополнительного усиления действия ингибиторов ацетилхолиunclassified

See 1 more Smart Citation

Modern Approaches to Diagnostics and Therapy of Alzheimer Disease

Преображенская¹

2017

Med. sov.

View full text Add to dashboard Cite

В статье приведены современные данные о причинах развития, методах диагностики и подходах к лечению болезни Альцгеймера. Особое внимание уделено патогенетической и симптоматической терапии этого заболевания, а также неле-карственным методам лечения. I.S. PREOBRAZHENSKAYA, MD, Prof., Sechenov First Moscow State University of the Ministry of Health of Russia MODERN APPROACHES TO DIAGNOSTICS AND THERAPY OF ALZHEIMER DISEASEThe article presents modern data on the causes of development, diagnostic methods and treatment approaches of Alzheimer's disease. Special attention is given to pathogenetic and symptomatic therapy of this disease, as well as non-drug treatments.

show abstract

“…The study was born following some clinical observations, one derived from the ASCOMALVA, an open label, double-blind study, which showed the effectiveness of a cholinergic precursor, choline alphoscerate, associated with donepezil, in slowing down Alzheimer's disease progression vs. donepezil alone [4]. Another study, the CITIRIVAD study, was a retrospective case-control study conducted on 174 consecutive outpatients aged ≥ 65 years old, affected with AD or mixed dementia (MD), mean age 81.3 ± 4.5 years old, treated with rivastigmine patches plus citicoline 1g daily vs. rivastigmine alone.…”

Section: Introductionmentioning

confidence: 99%